We propose an 14 month, milestone-driven, benchmarked research plan that extends a parent P20 Center grant focusing on bio-therapeutics development. The research will initially be executed by 6 newly hired academic research and technical positions at UCSD. Sustained and new employment in drug discovery, drug screening and drug development will be developed by partnerships with the San Diego's local biotechnology community. Specifically we will: (1) express a newly discovered recombinant neuropeptide protein that we identified in the parent grant (P20 GM078421). Analogs will be synthesized to identify functional domains and test agonists and antagonists. (2) develop high specificity monoclonal antibodies and create a quantitative ELISA assay to measure its role in disease. (3) evaluate preclinical models of wound repair by creating models of gene knock down and conditional knock outs to (a) establish its physiological relevance, (b) serve as models for drug discovery and (c) assist in converting the drug candidate to a drug lead. (4) identify its receptor by molecular cloning to establish an assay for drug discovery. (5) map the promoter to create a luciferase reporter transgenic mouse. (6) transfer technology generated to the private sector for further development. Funding will build on the success of the parent project, extend its scope, bring new fundamental skills to the laboratory, accelerate the tempo of scientific research and allow for significant job creation (and retention) by enabling hiring of additional staff, increasing hours of current part-time staff, and contracting for additional needed skills. The funded program will create 6 new full time positions, enable us to sustain 2 ongoing current research positions and with a successful outcome, we anticipate would generate an additional 5-15 new jobs in drug development research positions by technology transfer to the private biotechnology sector. Relevance: This research project describes 5 milestone and bench-marked specific AIMs that will create, test and validate a new therapeutic for wound healing. It will immediately create 6 full time positions and, if successful, its 6th AIM will create 5-15 new jobs by technology transfer to the private sector.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
3P20GM078421-05S1
Application #
7815960
Study Section
Special Emphasis Panel (ZGM1-PPBC-9 (RA))
Program Officer
Ikeda, Richard A
Project Start
2009-09-30
Project End
2010-07-31
Budget Start
2009-09-30
Budget End
2010-07-31
Support Year
5
Fiscal Year
2009
Total Cost
$420,206
Indirect Cost
Name
University of California San Diego
Department
Type
Schools of Pharmacy
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Costantini, Todd W; Meads, Morgan; Dang, Xitong et al. (2016) The Response to Burn Injury in Mice With Human Hematolymphoid Systems. Ann Surg 263:199-204
Podvin, Sonia; Miller, Miles C; Rossi, Ryan et al. (2016) The Orphan C2orf40 Gene is a Neuroimmune Factor in Alzheimer's Disease. JSM Alzheimers Dis Relat Dement 3:
Torbett, Bruce E; Baird, Andrew; Eliceiri, Brian P (2015) Understanding the rules of the road: proteomic approaches to interrogate the blood brain barrier. Front Neurosci 9:70
Dang, Xitong; Eliceiri, Brian P; Baird, Andrew et al. (2015) CHRFAM7A: a human-specific ?7-nicotinic acetylcholine receptor gene shows differential responsiveness of human intestinal epithelial cells to LPS. FASEB J 29:2292-302
Costantini, Todd W; Dang, Xitong; Coimbra, Raul et al. (2015) CHRFAM7A, a human-specific and partially duplicated ?7-nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury. J Leukoc Biol 97:247-57
Costantini, Todd W; Coimbra, Raul; Lopez, Nicole E et al. (2015) Monitoring Neutrophil-Expressed Cell Surface Esophageal Cancer Related Gene-4 after Severe Burn Injury. Surg Infect (Larchmt) 16:669-74
Kao, Steven; Shaterian, Ashkaun; Cauvi, David M et al. (2015) Pulmonary preconditioning, injury, and inflammation modulate expression of the candidate tumor suppressor gene ECRG4 in lung. Exp Lung Res 41:162-72
Lee, Jisook; Dang, Xitong; Borboa, Alexandra et al. (2015) Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation. Neuro Oncol 17:685-96
Podvin, Sonia; Dang, Xitong; Meads, Morgan et al. (2015) Esophageal cancer-related gene-4 (ECRG4) interactions with the innate immunity receptor complex. Inflamm Res 64:107-18
Baird, Andrew; Lee, Jisook; Podvin, Sonia et al. (2014) Esophageal cancer-related gene 4 at the interface of injury, inflammation, infection, and malignancy. Gastrointest Cancer 2014:131-142

Showing the most recent 10 out of 58 publications